{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI could not be estimated due to less number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI could not be estimated due to less number of participants with events.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI could not be estimated due to less number of participants with events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}],"units":"Participants"}],"description":"DoR was defined, in participants who achieved a response as time from the first date of response to the first date of recurrent or progression disease. Participants without recurrent or progression disease were censored on date of the last adequate disease assessment, date of initiation of anticancer treatment or death of death, whichever was the earliest.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.5 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.5 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 0.7 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 0.7 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG002","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 1.4 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG003","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 1.4 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received TTI-621 2.0 mg/kg infusion once weekly until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG004","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) 2.0 mg/kg"},{"description":"Participants with relapsed or refractory CTCL received a 2.0 mg/kg TTI-621 infusion once every 2 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG005","title":"Part 4: Ontorpacept (PF-07901800/TTI-621) Q2W / 2.0 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Analysis population included all the participants who received at least one dose of study treatment. Here, \"Number of Participants Analyzed\" refers to participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/death or withdrawal (maximum observation 6 years 10 months)","title":"Part 4: Duration of Response (DoR)","type":"SECONDARY","unitOfMeasure":"Months"}